In order to prevent IgE binding to its receptors, omalizumab—a monoclonal humanized anti‐IgE antibody that specifically binds to the constant region 3 (Cε3) of IgE—has been developed and has been shown to be effective for the treatment of a variety of allergic manifestations and in particular for severe IgE‐mediated asthma. Here, IGHE is linked to asthma.